Jonah Feldman


Topical Ruxolitinib Shown to be Effective and Tolerable in Cutaneous cGVHD

April 25th 2022

Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.

Resistance to CAR T-Cell Therapy Predicted by Epigenetic Biomarkers in Pediatric ALL

April 12th 2022

Resistance to CD19-directed CAR T-cell therapy was associated with molecular characteristics identified in pediatric patients with acute lymphoblastic leukemia.

CAR T-Cell Therapy Demonstrates Efficacy With or Without mRNA Vaccine in Solid Tumors

April 11th 2022

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results.

Atezolizumab Fails to Meet PFS End Point in Advanced Penile Squamous Cell Carcinoma

February 20th 2022

Atezolizumab with or without radiotherapy did not demonstrate efficacy in patients with advanced squamous cell carcinoma of the penis.

Leveraging Biomarkers in Endometrial Cancer Requires Careful Integration, More Research

January 27th 2022

Casey M. Cosgrove, MD, discussed the current state of biomarkers in the realm of endometrial cancer and how they may be optimally leveraged for prognostic and predictive purposes.

Sintilimab Plus Standard Chemotherapy Misses OS End Point in Metastatic Pancreatic Cancer

January 21st 2022

Sintilimab plus standard-of-care chemotherapy failed to demonstrate a significant improvement in overall survival and progression-free survival vs standard-of-care chemotherapy alone but did result in an improved objective response rate in patients with metastatic or recurrent pancreatic adenocarcinoma, according to findings from the phase 3 CISPD3 trial.

Acalabrutinib Shows Superior PFS, Safety Over Other Treatments in Relapsed/Refractory CLL

December 14th 2021

Acalabrutinib demonstrated an advantage in quality-adjusted survival compared with other treatments for relapsed/refractory chronic lymphocytic leukemia.

Ibrutinib Plus Venetoclax Induces Lower MRD Rate Vs FCR in Previously Untreated CLL

December 14th 2021

The combination of ibrutinib and venetoclax led to a lower rate of minimal residual disease compared with fludarabine, cyclophosphamide, and rituximab in patients with treatment-naïve chronic lymphocytic leukemia, according to preliminary findings from the phase 2 ERADIC trial.

Addition of Chemo to Endocrine Therapy Yields Survival Benefit in Premenopausal HR+/HER2- Breast Cancer

December 8th 2021

Significant outcome differences were observed in premenopausal vs postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who had 1 to 3 positive lymph nodes and received adjuvant chemotherapy as well as endocrine therapy.